These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 19287825

  • 1. Atorvastatin and amlodipine: the successful duet that led to Caduet.
    Cardiovasc J Afr; 2009; 20(1):87-8. PubMed ID: 19287825
    [No Abstract] [Full Text] [Related]

  • 2. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
    Frishman WH, Zuckerman AL.
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):675-81. PubMed ID: 15350169
    [Abstract] [Full Text] [Related]

  • 3. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM, Gemini-AALA Investigators.
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [Abstract] [Full Text] [Related]

  • 4. Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
    Ivanovic B, Tadic M.
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):544-9. PubMed ID: 23832643
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atorvastatin + amlodipine: new drug. Just a commercial ploy.
    Prescrire Int; 2007 Jun; 16(89):105. PubMed ID: 17582926
    [Abstract] [Full Text] [Related]

  • 7. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
    Fedacko J, Pella D, Jarcuska P, Sabol F, Kmec J, Lopuchovsky T, Merkovska L, Jedlickova L, Janicko M, Sajty M.
    Adv Ther; 2013 Jan; 30(1):60-70. PubMed ID: 23328937
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Caduet treats two cardiovascular conditions at once.
    Wimett L, Laustsen G.
    Nurse Pract; 2004 Jun; 29(6):56-7. PubMed ID: 15257126
    [No Abstract] [Full Text] [Related]

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 11. Amlodipine/atorvastatin (Caduet) for preventing heart disease.
    Wilson SA, Sanford A.
    Am Fam Physician; 2006 Mar 15; 73(6):1067-8. PubMed ID: 16570743
    [No Abstract] [Full Text] [Related]

  • 12. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
    Devabhaktuni M, Bangalore S.
    Vasc Health Risk Manag; 2009 Mar 15; 5(1):377-87. PubMed ID: 19475775
    [Abstract] [Full Text] [Related]

  • 13. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
    Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D.
    Am J Hypertens; 2003 Sep 15; 16(9 Pt 1):715-8. PubMed ID: 12944027
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
    Cowie MR.
    Int J Clin Pract; 2005 Jul 15; 59(7):839-46. PubMed ID: 15963213
    [Abstract] [Full Text] [Related]

  • 15. Atorvastatin calcium plus amlodipine for the treatment of hypertension.
    Delgado-Montero A, Zamorano JL.
    Expert Opin Pharmacother; 2012 Dec 15; 13(18):2673-85. PubMed ID: 23140185
    [Abstract] [Full Text] [Related]

  • 16. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Pharmacoeconomics; 2009 Dec 15; 27(3):221-30. PubMed ID: 19354342
    [Abstract] [Full Text] [Related]

  • 17. Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
    Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M, CRUCIAL trial investigators.
    Vasc Health Risk Manag; 2014 Dec 15; 10():145-56. PubMed ID: 24707184
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
    Kiberd BA.
    Nat Clin Pract Nephrol; 2006 Jul 15; 2(7):354-5. PubMed ID: 16932460
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
    Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, Sun W, Lee E, Neutel JM, AVALON Investigators.
    J Clin Hypertens (Greenwich); 2006 Aug 15; 8(8):571-81; quiz 582-3. PubMed ID: 16896273
    [Abstract] [Full Text] [Related]

  • 20. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
    Martín-Ventura JL, Tuñon J, Duran MC, Blanco-Colio LM, Vivanco F, Egido J.
    J Am Soc Nephrol; 2006 Dec 15; 17(12 Suppl 3):S189-93. PubMed ID: 17130260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.